CASTLE BIOSCIENCES INC (CSTL) News
Filter CSTL News Items
CSTL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CSTL News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CSTL News From Around the Web
Below are the latest news stories about CASTLE BIOSCIENCES INC that investors may wish to consider to help them evaluate CSTL as an investment opportunity.
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 ResultsFRIENDSWOOD, Texas, January 12, 2025--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2024. |
FDA Accepts J&J's Filing for Autoimmune Disease Drug NipocalimabJNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients. |
FDA Accepts Agios' sNDA for Pyrukynd in ThalassemiaIf approved, AGIO's Pyrukynd will be the first oral therapy for all thalassemia subtypes. A final decision is expected by Sep. 7. |
CorMedix Stock Rises on Q4 Preliminary Sales Beating EstimatesCRMD reports $31 million in preliminary sales from its sole marketed product in Q4, surpassing its previous guidance of breaking even by 2024. |
FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain ReliefPacira receives FDA approval for a new iovera Smart Tip aimed at expanding pain management capabilities to deeper nerves like the medial branch nerve. |
AbbVie Cuts 2024 EPS Guidance to Include Acquisition CostsABBV lowers adjusted earnings guidance for 2024 from $10.90-$10.94 per share to $10.02-$10.06 after incurring $1.6 billion in acquisition expenses in Q4. |
Castle Biosciences gains New York state approval for Barrett’s oesophagus testCastle Biosciences' TissueCypher test predicts a patient’s risk of progression from Barrett’s oesophagus to oesophageal cancer. |
Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus TestFRIENDSWOOD, Texas, January 06, 2025--Castle Biosciences has received assay approval from the New York State Department of Health (NYSDOH) for its TissueCypher Barrett’s Esophagus test. |
Here's Why Arcutis Stock More Than Doubled in Market Value in One YearThe rally in ARQT's stock could be attributed to the encouraging regulatory updates seeking label expansion for its sole marketed drug. |
MESO Stock Surges 80% in a Month After FDA Approval of GVHD DrugMesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older. |